Long-term Follow up of Congenital Adrenal Hyperplasia Patients with Hyponatremia.
- Author:
Jun Hyuk SONG
1
;
Kyu Ha LEE
;
Sung Do KIM
;
Byoung Soo CHO
Author Information
- Publication Type:Case Report
- Keywords: Congenital adrenal hyperplasia; 21-hydroxylase deficiency; Hyponatremia; Adrenal mass; Adrenal tumor
- MeSH: Adenoma; Adrenal Hyperplasia, Congenital*; Adrenalectomy; Adrenocorticotropic Hormone; Aldosterone; Androgens; Compliance; Fludrocortisone; Follow-Up Studies*; Humans; Hydrocortisone; Hyperandrogenism; Hyponatremia*; Steroid 21-Hydroxylase; Virilism
- From:Electrolytes & Blood Pressure 2007;5(2):140-146
- CountryRepublic of Korea
- Language:English
- Abstract: Congenital adrenal hyperplasia (CAH) caused by 21-hydroxylase deficiency is an autosomal recessive disease, which leads to cortisol and aldosterone deficiency and hyperandrogenism. Typical medical treatment includes oral glucocorticoid and mineralocorticoid administration to suppress adrenal androgens and to compensate for adrenal steroid deficiencies. Usually, they have been managed with hydrocortisone (cortisone) and fludrocortisone (florinef). However, some patients stopped taking medicine without the doctor's consent. Among these patients, four cases of CAH patients showing the presence of hyponatremia as an initial electrolyte disorder were found with adrenal adenoma discovered by abdominal computerized tomography scan. Hypersecretion of adrenocorticotrophic hormone may play a role in the development of adrenal tumor and chronic poor compliance to therapy appears to be associated with development of the tumor. Two cases were managed with adrenalectomy because of increasing adrenal tumor size and virilization. Whereas the other two cases did not increase in size and were observed without adrenalectomy. Therefore, it is important that patients with CAH maintain steroid medication to avoid the appearance of adrenal tumor.
